Abstract 1491 Modeling Nicotine, AT-1001, & Varenicline at the α3β4 Nicotine Acetylcholine Receptor

The escalating global prevalence of nicotine addiction, particularly among younger populations, has been linked to the increasing use of e-cigarettes, commonly known as vapes. Approximately 1.63 million students (ages 11-18) currently use vapes, reflecting a concerning trend of nicotine dependence among adolescents. As the number of nicotine addiction cases continues to rise, the development of an anti-addiction drug market is evolving to address this urgent public health issue. One such treatment is varenicline that acts as a partial agonist at the α3β4 nicotine acetylcholine receptor nAChR, a key target for smoking cessation therapies.